EY
EyePoint Pharmaceuticals, Inc.
EYPT · NASDAQ
$4.56 +0.00% (+$0.00)
1M -64.96%
Market Cap $384.0M
P/E Ratio -
Div. Yield -
ROE 135.81%
Piotroski F-Score Weak
2/9Valuation
40 /100
Fair P/S 137.68x
P/B 2.31x
P/E N/A
Growth
22 /100
Declining Rev. growth 8.83%
Book val. growth 47.00%
EPS growth N/A
Profitability
17 /100
Weak Gross margin 41.77%
Net margin 10,994.70%
Op. margin 11,365.20%
Quality
0 /100
Poor ROIC 167.81%
ROE 135.81%
ROA 134.38%
Debt
100 /100
Low Debt/Equity 0.13x
Current ratio 4.50x
Int. coverage N/A
Stability
37 /100
Moderate Beta 1.74x
Rev. volatility 19.37%
EPS volatility 38.17%
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o EYPT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jay S. Duker
Employees
214
Headquarters
Watertown
Nadchodzące wydarzenia
04 LIS
Earnings
Upcoming earnings report